Positive 96-Week Results for Darunavir-Based Single-Tablet Regimen for HIV

A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load

New trial results presented at HIV Glasgow in Scotland indicate that the combination of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (D/C/F/TAF, SYMTUZA, Janssen) is a safe and effective treatment for HIV-1 infection in treatment-naïve and certain virologically suppressed adults.

The combination of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg was approved in July 2018 as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in treatment-naïve and certain virologically-suppressed adults based on the results of the AMBER and EMERALD trials.

A total of 85% of AMBER study participants (308/362) achieved virologic suppression (viral load <50 copies/mL) at week 96 when treated with D/C/F/TAF for HIV infection, according to a statement from Janssen. Six-percent of participants (20/362) had virologic failure (viral load >50 c/mL); however, none of the participants experienced darunavir, primary protease inhibitor, or tenofovir resistance-associated mutations.

For more on this study, visit ContagionLive.com.